-- Haemophilia B segment will see high growth over the
forecast period, finds Frost & Sullivan
LONDON, May 7, 2015 /PRNewswire/ -- Increased uptake
of recombinant therapies and prophylactic use, coupled with
improved diagnosis of haemophilia, is expected to drive the
associated therapeutics market. Recombinant therapies are likely to
command a premium price and fuel growth in developed markets, while
heightened access to treatment and larger patient volumes due to
more funding for critical care are anticipated to contribute to
demand in emerging markets.
Logo -
http://photos.prnewswire.com/prnh/20150507/214499LOGO
New analysis from Frost & Sullivan, Global Haemophilia
Therapeutics Market, finds that the market earned revenues of
$9.98 billion in 2014 and estimates
this to reach $13.43 billion in
2019. The study covers haemophilia A and Von Willebrand disease
(factor VIII/von Willebrand factor), haemophilia B (factor IX),
inhibitors (factor VIIa), and novel therapies in the pipeline.
For complimentary access to more information on this research,
please visit:
http://corpcom.frost.com/forms/EU_PR_AZanchi_MAD9-52_30Apr15.
Currently, plasma-derived therapies account for nearly 30
percent of haemophilia A therapeutics sales, 41 percent of
haemophilia B therapeutics sales, and 25 percent of the inhibitors
market. Over time, however, adults are likely to switch to
prophylaxis therapies due to the lucrative benefits offered by
these long-lasting products compared to plasma-derived
products.
"The haemophilia B segment is set to gain traction as
newer products are far more convenient than established therapies,"
said Frost & Sullivan Healthcare Industry Analyst
Aiswariya Chidambaram. "In contrast, the haemophilia A
segment could lose some pace, with none of the recently launched or
pipeline FVIII therapies able to extend product half-life by more
than 60 percent."
With several new recombinant products in the market, a rise in
price pressure is anticipated. This, along with negotiated
discounts in emerging markets, could hamper the development of the
global haemophilia therapeutics market.
Newer recombinant therapies will gradually capture share from
leading players, posing more of a long-term threat to the market.
This is because market entrants such as Biogen Idec / SOBI
do not have well-established marketing/sales teams or good
relationships with haematologists unlike global big pharma
companies.
"Although several products for bleeding disorders are expected
to be introduced in the next few years, most of them are being
developed by current manufacturers," noted Chidambaram. "While the
majority of companies strive to improve recombinant factor
replacement based on novel technologies, very few companies
are exploring completely different approaches to develop
haemophilia therapies."
Global Haemophilia Therapeutics Market is part of the
Life Sciences Growth Partnership Service program. Frost
& Sullivan's related studies include: US Hematology Diagnostics
Market, Product and Pipeline Assessment of the Global Orphan Drugs
Market, A Competitive Analysis of the Global Breast Cancer
Therapeutics Market, and A Product and Pipeline Analysis of the
Opioid Therapeutics and Drug Delivery Market. All studies included
in subscriptions provide detailed market opportunities and industry
trends evaluated following extensive interviews with market
participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in
collaboration with clients to leverage visionary innovation that
addresses the global challenges and related growth opportunities
that will make or break today's market participants. For more than
50 years, we have been developing growth strategies for the global
1000, emerging businesses, the public sector and the investment
community. Is your organization prepared for the next profound wave
of industry convergence, disruptive technologies, increasing
competitive intensity, Mega Trends, breakthrough best practices,
changing customer dynamics and emerging economies?
Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com